Adjuvant Radiotherapy After Radical Cystectomy for Bladder Cancer
Consider adjuvant radiotherapy (45-50.4 Gy) for patients with pT3/pT4 pN0-2 urothelial bladder cancer after radical cystectomy, particularly those with positive surgical margins, positive lymph nodes, or extranodal extension.
Primary Indications for Adjuvant RT
The NCCN guidelines specifically recommend considering adjuvant pelvic RT for patients meeting these pathologic criteria 1:
- pT3 or pT4 disease (locally advanced)
- Any nodal involvement (pN0-2)
- Positive surgical margins
- Extranodal extension
- Fewer than 10 lymph nodes removed (inadequate nodal assessment)
Evidence Base and Clinical Context
The rationale stems from high pelvic failure rates in locally advanced disease: 20-45% pelvic recurrence and 10-50% 5-year survival depending on risk factors 1. Patients with positive margins and/or positive lymph nodes face particularly dire outcomes with 40-45% pelvic failure rates by 5 years 1.
Supporting Evidence
A recent phase III randomized trial (BART) demonstrated that adjuvant RT significantly improved 2-year locoregional recurrence-free survival: 87.1% versus 76.0% (HR 0.43, P=0.04) 2. This represents the highest quality evidence available, though overall survival benefit remains unproven. An earlier phase II trial showed 3-year local control of 96% versus 69% with chemoradiation versus chemotherapy alone, though DFS and OS improvements were not significant 1.
Important caveat: While local control improves substantially, no conclusive data demonstrate overall survival improvements 1. The benefit appears primarily in preventing locoregional recurrence rather than extending life.
Treatment Specifications
Radiation Dose and Technique
- 45-50.4 Gy in 25-28 fractions to pelvic lymph nodes and cystectomy bed 1, 2
- Boost to 54-60 Gy for involved margins or extranodal extension if feasible within normal tissue constraints 1
- Use intensity-modulated RT (IMRT) with daily image guidance 2, 3
- Employ stoma-sparing techniques 2
Target Volumes
Treatment fields should encompass 1:
- Cystectomy bed (regardless of margin status per updated consensus 4)
- Pelvic lymph node regions: hypogastric, obturator, internal/external iliac, perivesical, sacral, presacral nodes
- Entire common iliac region 4
Integration with Systemic Therapy
Critical sequencing consideration: If the patient did not receive neoadjuvant chemotherapy, it may be reasonable to "sandwich" adjuvant RT between cycles of adjuvant chemotherapy 1. However, concurrent chemotherapy with adjuvant RT remains investigational and requires further study 1.
The safety profile is acceptable: late grade ≥3 GI toxicity is low (approximately 8-10%) 1, 3, and acute grade 3+ toxicity is minimal 3.
Risk Stratification Algorithm
Use this hierarchy to identify candidates:
Highest Priority (offer RT):
- Positive surgical margins
- pN+ disease (any nodal involvement)
- Extranodal extension
High Priority (strongly consider RT): 4. pT4 disease 5. pT3 with lymphovascular invasion 6. Inadequate nodal dissection (<10 nodes) with pT3-4 disease
Moderate Priority (consider RT): 7. pT3 disease alone without other risk factors
Common Pitfalls
- Don't wait for symptoms: Adjuvant RT should be initiated within 90 days of cystectomy for optimal benefit 5
- Don't omit cystectomy bed: Even with negative margins, include the cystectomy bed in treatment volumes based on pattern of failure data 4
- Don't use concurrent chemotherapy routinely: Unlike definitive chemoradiation, concurrent sensitizing chemotherapy with adjuvant RT lacks safety/efficacy data 1
- Don't substitute for systemic therapy: RT addresses locoregional control but doesn't replace chemotherapy for high-risk features 1
Patients Who Should NOT Receive Adjuvant RT
- pT2 or less with negative nodes and negative margins (low risk, no benefit expected) 1
- Patients with distant metastases at time of consideration
- Those with prohibitive comorbidities precluding safe RT delivery
The 2024 EAU guidelines note that preoperative RT should not be offered as it only results in downstaging without survival improvement 6. The role is specifically in the adjuvant setting for high-risk pathologic features.